AVEO PHARMACEUTICALS, INC. AVEO Cash Flow

Aveo pharmaceuticals, inc. (AVEO)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities
Net income (loss)
-8,381	-4,461	16,429	-3,135	555	21,818	-22,163	4,004	-8,988	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-8,840	-	-4,966	-8,606	-7,710	-6,589	7,918	-5,456	-10,874	-13,894	-14,436	-17,959	-6,450	-16,725	-24,306	-31,913	-34,085	-21,480	-30,122	-29,546	-33,246	-25,169	-23,818	-5,731	85,366
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Impairment of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	232	0	0	5,098	2,502	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	23	0	2	5	6	97	4,976	4,488	3,455	1,074	852	838	936	968	971	900	758	606	600	546	456	433	393	372
Accretion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	25	199	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss (gain) on disposal of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-23	15	-265	20	-	-	-	-	-6	0	-27	-50	-	-	-	-	-	-	-	-
Stock-based compensation
543	504	686	584	584	658	684	621	583	315	291	276	207	170	205	234	390	-48	342	411	427	230	1,212	648	718	778	1,184	-610	2,588	1,897	2,048	1,860	2,202	1,623	1,687	1,411	1,182
Non-cash interest expense
109	122	134	145	166	157	146	142	111	123	123	134	134	134	135	110	86	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash change in fair value of PIPE Warrant liability
-2,648	-2,506	1,954	-2,210	-8,815	-26,431	16,172	-11,125	1,465	-14,207	23,538	23,925	484	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash charge for settlement costs (Note 13)
-	-	-	-	-	0	0	-709	42	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100	119	125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-39	-46	-54	-	-69	-75	-81	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	82	82	135	133	193	193	269
Amortization of premium and discount on investments
51	-	-	-	-	0	-1	3	-5	-32	-24	-15	3	-8	7	-10	-3	-1	0	-19	-14	-3	-21	-77	-120	-171	-196	-335	-339	-284	-732	-645	-785	-1,000	-1,168	-965	-668
Changes in operating assets and liabilities:
Restricted Cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,862	0	-98	-37	-	-	-	-	37	0	0	-42	-	-	-	-	46	0	1	97
Accounts receivable
1,148	541	479	-1,960	-455	2,682	-629	373	198	-1,973	1,930	-231	-351	37	-312	-434	-2,905	2,307	14	1,373	-1,394	683	423	-19	270	-7,909	996	-1,284	-11,468	11,351	116	-307	2,279	-2,537	-19,023	20,723	7,656
Tenant improvement allowance receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-196	-14,706	1,581	7,488	-	-	241	300	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-559	208	197	578	-241	-204	-251	-70	-249	-488	176	-244	-128	-263	782	313	-492	236	-64	281	-337	-1,773	-402	1,623	-951	-989	-1,442	-765	17	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,724	-2,565	-	-3,731	-4,922	9,363
Other noncurrent assets
1,383	-	-	-	-	-4	-3	-4	-4	-168	-169	-333	-285	-101	661	286	-19	-21	-24	-25	-26	194	-52	-160	-32	-13	-27	-37	46	13	-48	258	-23	-109	0	-188	-38
Accounts payable
1,499	-717	220	-146	-1,390	516	161	-558	944	495	-1,420	84	1,091	1,006	-902	1,741	-1,085	1,138	-1,280	-1,052	-626	1,592	-1,847	880	-1,618	-1,899	-1,093	-853	-2,545	369	5,983	-3,279	-1,349	-774	-3,260	1,114	2,577
Accrued contract research
-580	-	391	-1,644	98	-	262	-346	-984	-	1,253	1,099	1,146	-	52	1,466	-660	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other accrued liabilities
-860	531	250	-365	-778	-492	1,506	-278	-496	837	261	92	-263	6	80	-92	-603	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current liabilities
438	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Settlement liability (Note 13)
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-4,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-493	-493	-494	-493	546	704	-335	-336	1,019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,900	-	-8,026	3,692	71	-544	-1,657	-3,509	-2,128	1,185	-2,901	6,637	333	992	3,020	-26,535	26,691
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-128	-	-992	-166	-203	2,354	726	-77	-76	384	-871	-1,845	-15,291	-323	-323	-323	-324	-323	-323	-324	-323	-324	-1,259	-3,509	-7,132
Deferred research and development reimbursements
117	-140	26	-129	-118	-74	-124	-197	-274	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-current liabilities
592	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease exit obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	0	-1,860	-3,345	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-5,369	-5,200	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,523	-	1,677	2,022	2,369	-	-	-	-	-	-	-	-
Other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-120	42	41	152	-57	-58	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,466	1,388	-18	27	-60	-48	-57
Net cash used in operating activities
-11,687	-7,371	18,919	-6,011	-8,456	-6,617	-2,807	-9,084	-6,518	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-21,608	-	-24,065	-27,667	-30,626	-19,907	861	-47,361	92,858
Investing activities
Purchases of property and equipment
100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	67	1,042	4,079	7,754	657	1,036	1,213	762	5,765	1,839	1,237	1,107	796	591	922	319
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-5,408	-	-8,704	-4,590	-10,319	11	9,009	-11,430	-15,820	-11,025	-8,003	-15,404	-19,816	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of marketable securities
7,152	-	-	-	-	0	0	-68	6,801	-	-	-	-	750	8,722	14,203	5,746	7,504	2,773	2,760	6,048	4,250	0	5,002	33,054	21,166	8,163	97,111	48,951	84,588	32,577	43,345	34,074	67,066	108,455	127,465	73,284
Proceeds from maturities and sales of marketable securities
15,000	-	-	-	-	0	0	10,775	14,537	9,500	6,698	0	8,252	10,928	4,486	5,750	7,500	2,500	275	7,275	1,500	7,660	18,140	25,339	58,628	33,248	50,415	80,115	27,351	75,418	86,370	84,304	93,687	84,702	72,257	42,284	35,552
Net cash provided by investing activities
7,748	-	-	-	-	0	0	10,843	7,736	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-22,362	-	51,954	39,722	58,506	16,840	-36,789	-86,103	-38,051
Financing activities
Proceeds from issuance of common stock and warrants, net of issuance costs
-	0	10	17,757	7,512	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, net of issuance costs
-	-	-	-	-	-	-	-	518	-	259	8,774	12,261	-	-	-	-	-	-	-	4,353	-	-	-	-	-1	0	0	53,638	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock to related parties
-	-	-	-	-	-	-	-	-	-	0	0	3,210	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of stock for stock-based compensation arrangements
-	-	-	-	-	265	44	170	15	-	-	-	-	1	2	31	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of principal of loan payable (Note 6)
2,389	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	20	293	928	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	8,252	-	-4,243	-8,453	1,754	-5,012	-2,492	4,808	-3,620	3,351	17,281	16,258	17,820	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options and issuance of common and restricted stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	202	73	-	161	1	29	-	-	-	-	-	-	-	-	-	-	-	-
Payments of debt issuance costs
-	-	-	-	-	-	0	0	540	-	-	-	-	0	0	100	15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	295	70	-	-	662	183	-	862	1,236	478
Principal payments on loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,095	2,924	2,836	2,757	0	1,433	3,828	2,524	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	15,471	-	-14	20,318	-13	-3,104	1,456	-1,147	1,669	0	7,340	-3,827	-2,495	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from refinancing of loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3,672	-	-	-	-
Principal payments on loans payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2,172	-	-	-	-
Net cash (used in) provided by financing activities
-2,389	-2,581	-1,497	22,760	7,512	10,636	5,126	170	-7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53,708	-	452	662	1,683	660	828	113,401	478
Net decrease in cash and cash equivalents
-6,328	-	-	-	-944	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	1,929	1,211	-	-14,506	-2,551	18,315	2,726	-12,961	7,275	-8,578	-8,105	7,973	-7,769	-17,771	-7,674	16,618	-2,973	-4,491	406	16,598	-52,076	9,738	-37,967	28,341	12,717	29,563	-2,407	-35,100	-20,063	55,285
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	26	-2	-27	7	-4	-	-	-	-
Supplemental cash flow information
Cash paid for interest
368	432	510	522	507	500	494	483	509	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use asset obtained in exchange for operating lease liabilities
1,225	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	446	-	457	330	301	364	457	545	617	571	407	487	553	633	713	782	788	798	805	770	731	752	760	760	744
Non-cash operating activity
Non-cash adjustment
Increase to deferred revenue due to adoption of ASC 606 - transition adjustment on January 1, 2018
-	-	-	-	-	-	0	0	2,711	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-cash activity
Deferred offering costs accrued at period end
-	-	-	-	212	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0